Alnylam Pharmaceuticals | ALNY - Cash And Equivalent



Alnylam Pharmaceuticals reported $1.11B in Cash and Equivalent for its fiscal quarter ending in June of 2025.


Cash And Equivalent Change Date
Acadia Pharmaceuticals USD 762M 80.42M Jun/2025
Agios Pharmaceuticals USD 80.87M 1.91M Jun/2025
Alnylam Pharmaceuticals USD 1.11B 94.03M Jun/2025
Amgen USD 8.03B 782M Jun/2025
Arrowhead Research USD 129.79M 55.92M Jun/2025
BioMarin Pharmaceutical USD 1.21B 601.78M Jun/2025
Incyte USD 2.42B 13.08M Jun/2025
Ionis Pharmaceuticals USD 297.3M 33.11M Jun/2025
Moderna USD 1.28B 344M Jun/2025
Neurocrine Biosciences USD 264M 69.9M Jun/2025
Novartis USD 6.66B 4.8B Jun/2025
PTC Therapeutics USD 1.02B 1.01B Jun/2025
Regeneron Pharmaceuticals USD 2B 1.09B Jun/2025
Sanofi 15.36B 7.92B Jun/2025
Sarepta Therapeutics USD 510.6M 269.73M Jun/2025
Takeda JPY 350.01B 35.11B Jun/2025
Tectonic Therapeutic USD 287.38M 146.14M Jun/2025
Ultragenyx Pharmaceutical USD 166.11M 396.9M Jun/2025
Vertex Pharmaceuticals USD 6.38B 1.71B Jun/2025
Xencor USD 44.44M 4.77M Jun/2025